Ramesh Babu1, Thiyagarajan Chittibabu2, Sugandh Chadha2. 1. Department of Pediatric Urology, Sri Ramachandra Medical College and Research Institute, Porur, Chennai, Tamil Nadu, 600116, India. drrameshbabu1@gmail.com. 2. Department of Pediatric Urology, Sri Ramachandra Medical College and Research Institute, Porur, Chennai, Tamil Nadu, 600116, India.
Abstract
AIMS: This pilot study aims to assess the short-term efficacy and safety of mirabegron in valve bladder, an important cause of persistent hydronephrosis after successful treatment of posterior urethral valves (PUV). METHODS: Twenty-two patients with early valve bladder (no residual PUV; persistent hydronephrosis, wetting and urodynamic evidence of detrusor overactivity) were included. Three subjective parameters: frequency, wetting episodes; patient perception of bladder condition score (PPBC) and four objective parameters: uroflow index (UI = Qave/Qmax), voided volume (VV = voided volume/ expected bladder capacity), maximum filling pressure (P det-max) and society of fetal urology (SFU) hydronephrosis grading were analysed pre- and post-3-month treatment with mirabegron (0.5-1 mg/kg/day). All patients were observed for heart rate, BP, ECG changes during therapy. RESULTS: There was significant reduction (p = 0.001) in mean frequency (pre 15; post 10), wetting episodes (pre 5; post 2) and PPBC (pre 4; post 3). There was significant improvement (p = 0.01) in mean UI (pre 0.3; post 0.5), VV (pre 0.54; post 0.72), Pdet-max (pre 42; post 25) and hydronephrosis grade (pre 3.5; post 2.2). There were no significant side effects. CONCLUSION: This pilot study establishes short-term efficacy and safety of mirabegron in valve bladder with overactivity. Further larger long-term studies are warranted.
AIMS: This pilot study aims to assess the short-term efficacy and safety of mirabegron in valve bladder, an important cause of persistent hydronephrosis after successful treatment of posterior urethral valves (PUV). METHODS: Twenty-two patients with early valve bladder (no residual PUV; persistent hydronephrosis, wetting and urodynamic evidence of detrusor overactivity) were included. Three subjective parameters: frequency, wetting episodes; patient perception of bladder condition score (PPBC) and four objective parameters: uroflow index (UI = Qave/Qmax), voided volume (VV = voided volume/ expected bladder capacity), maximum filling pressure (P det-max) and society of fetal urology (SFU) hydronephrosis grading were analysed pre- and post-3-month treatment with mirabegron (0.5-1 mg/kg/day). All patients were observed for heart rate, BP, ECG changes during therapy. RESULTS: There was significant reduction (p = 0.001) in mean frequency (pre 15; post 10), wetting episodes (pre 5; post 2) and PPBC (pre 4; post 3). There was significant improvement (p = 0.01) in mean UI (pre 0.3; post 0.5), VV (pre 0.54; post 0.72), Pdet-max (pre 42; post 25) and hydronephrosis grade (pre 3.5; post 2.2). There were no significant side effects. CONCLUSION: This pilot study establishes short-term efficacy and safety of mirabegron in valve bladder with overactivity. Further larger long-term studies are warranted.
Authors: Jee Soo Park; Yong Seung Lee; Cho Nyeong Lee; Sung Hoon Kim; Sang Woon Kim; Sang Won Han Journal: World J Urol Date: 2018-12-03 Impact factor: 4.226
Authors: Catalina Tessi; María Tatiana Szklarz; Felicitas López Imizcoz; Javier Ruiz; Santiago Weller; Cristian Sager; Pablo Omar Agustin Schiavo; Pablo Horacio Lechuga; Antonio Luna; Juan Pablo Corbetta Journal: J Pediatr Urol Date: 2020-12-05 Impact factor: 1.830
Authors: Konrad Futyma; Łukasz Nowakowski; Michał Bogusiewicz; Alicja Ziętek; Andrzej P Wieczorek; Tomasz Rechberger Journal: Neurourol Urodyn Date: 2015-10-09 Impact factor: 2.696